Robin Dewar
Overview
Explore the profile of Robin Dewar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huapaya J, Gairhe S, Kanth S, Tian X, Demirkale C, Regenold D, et al.
Front Immunol
. 2024 Sep;
15:1448780.
PMID: 39324144
Background: Limited data are available describing the effects of SARS-CoV-2 breakthrough infections on the plasma proteome. Methods: PCR-positive SARS-CoV-2 patients, enrolled in a natural history study, underwent analysis of the...
2.
Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, et al.
J Infect Dis
. 2024 Sep;
PMID: 39269490
Background: Biomarker guided therapy could improve management of COVID-19 inpatients. Although some results indicate that antibody tests are prognostic, little is known about patient management using point-of-care (POC) antibody tests....
3.
Jilg N, Giganti M, Chew K, Shaw-Saliba K, Ritz J, Moser C, et al.
Clin Infect Dis
. 2024 Jul;
79(4):920-927.
PMID: 39018444
Background: Reliable biomarkers of coronavirus disease 2019 (COVID-19) outcomes are critically needed. We evaluated associations of spike antibody (Ab) and plasma nucleocapsid antigen (N Ag) with clinical outcomes in nonhospitalized...
4.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, et al.
J Infect Dis
. 2024 Apr;
230(3):624-634.
PMID: 38657001
Background: Although antivirals remain important for the treatment COVID-19, methods to assess treatment efficacy are lacking. Here, we investigated the impact of remdesivir on viral dynamics and their contribution to...
5.
Alipanah-Lechner N, Hurst-Hopf J, Delucchi K, Swigart L, Willmore A, LaCombe B, et al.
Crit Care
. 2024 Feb;
28(1):56.
PMID: 38383504
Background: Despite evidence associating inflammatory biomarkers with worse outcomes in hospitalized adults with COVID-19, trials of immunomodulatory therapies have met with mixed results, likely due in part to biological heterogeneity...
6.
Singh K, Natarajan V, Dewar R, Rupert A, Badralmaa Y, Zhai T, et al.
AIDS
. 2023 Aug;
37(14):2119-2130.
PMID: 37555786
Objectives: People with HIV-1 (PWH) on effective antiretroviral therapy (ART) continue to exhibit chronic systemic inflammation, immune activation, and persistent elevations in markers of HIV-1 infection [including HIV-DNA, cell-associated HIV-RNA...
7.
Lisco A, Lange C, Manion M, Kuriakose S, Dewar R, Gorelick R, et al.
Nat Med
. 2023 Jun;
29(6):1364-1369.
PMID: 37322122
Reservoirs of HIV maintained in anatomic compartments during antiretroviral therapy prevent HIV eradication. However, mechanisms driving their persistence and interventions to control them remain elusive. Here we report the presence...
8.
Huapaya J, Higgins J, Kanth S, Demirkale C, Gairhe S, Aboye E, et al.
J Infect Dis
. 2023 Feb;
228(1):46-58.
PMID: 36801946
Background: Data on cellular immune responses in persons with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following vaccination are limited. The evaluation of these patients with SARS-CoV-2 breakthrough infections...
9.
Wick K, Leligdowicz A, Willmore A, Carrillo S, Ghale R, Jauregui A, et al.
Crit Care
. 2022 Sep;
26(1):278.
PMID: 36104754
Background: Studies quantifying SARS-CoV-2 have focused on upper respiratory tract or plasma viral RNA with inconsistent association with clinical outcomes. The association between plasma viral antigen levels and clinical outcomes...
10.
Sasson J, Donlan A, Ma J, Haughey H, Coleman R, Nayak U, et al.
Open Forum Infect Dis
. 2022 Aug;
9(8):ofac343.
PMID: 35959207
Background: Based on studies implicating the type 2 cytokine interleukin 13 (IL-13) as a potential contributor to critical coronavirus disease 2019 (COVID-19), this trial was designed as an early phase...